Joint Clinical Trials Office

You are here

Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

Clinical Trial Details

This phase III ALCHEMIST trial studies how well erlotinib hydrochloride compared to observation works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Key Eligibility: 
  • Non-small cell lung cancer, which has been removed by a surgeon 
  • Registered to ALCHEMIST screening protocol A151216 

    

Study contact by location

Brooklyn

Contact(s)

Tricia L. Ellis
(718) 330-7441
tre2004@nyp.org

Upper East Side - Manhattan

Contact(s)

Victoria Dai
(212) 746-2225
vid9053@med.cornell.edu

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:

1502015943

ClinicalTrials.gov:

NCT02193282

Status

Open to Enrollment

Age Group

Adult

Sponsor